Determinants of Left Ventricular Hypertrophy in Hypertensive Patients: Identification of High-Risk Patients by Metabolic, Vascular, and Inflammatory Risk Factors

Abstract

Left ventricular hypertrophy (LVH) is recognized as an independent predictor of cardiovascular morbidity and mortality in hypertensive patients. Thus, it is critical to understand the mechanisms underlying the development of LVH for formulation screening and treatment strategies. This study was designed to determine the association between echographically determined LVH measures and markers of inflammation, neurohormonal activity, glomerular function, oxidative stress, insulin resistance, and vascular endothelial function. In this study, 129 hypertensive subjects were evaluated for lipids, glucose, HbA1C, insulin, homeostasis model assessment-insulin resistance, C-reactive protein (CRP), urinary microalbumin, homocysteine, aldosterone, renin, and endothelin. LVH parameters including interventricular septum thickness, posterior wall thickness (PWT), and left ventricular mass index (LVMI) were assessed echographically. Serum aldosterone levels were significantly positively associated with left ventricular mass (LVM) and marginally positively associated with LVMI and PWT. Both LVM and LVMI were significantly elevated in subjects with high versus normal serum aldosterone levels (p = 0.018 for LVM and p = 0.050 for LVMI). Serum endothelin was positively associated with LVM and LVMI. In multiple linear regression analysis, aldosterone remained a significant predictor of LVM (standardized β = 0.229, p = 0.024), and endothelin a marginally significant predictor of LVM (standardized β = 0.178, p = 0.077). Among serum lipids, high-density lipoprotein cholesterol only had a significant inverse association with LVM and PWT. Homocysteine as well as CRP were significantly positively associated with LVM and LVMI in females. This study found that aldosterone and endothelin levels are the most important independent determinants of LVH in hypertensive subjects. These markers may be useful to identify asymptomatic hypertensive subjects at risk for heart failure.

Keywords

cardiovascular disease - cardiovascular risk factors - hypertension - hypercholesterolemia - creatinine - high-sensitivity C-reactive protein

• References

• 1 Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322 (22) 1561-1566
• 2 Palmieri V, de Simone G, Roman MJ, Schwartz JE, Pickering TG, Devereux RB. Ambulatory blood pressure and metabolic abnormalities in hypertensive subjects with inappropriately high left ventricular mass. Hypertension 1999; 34 (5) 1032-1040
• 3 Anan F, Yonemochi H, Masaki T , et al. High-density lipoprotein cholesterol and insulin resistance are independent and additive markers of left ventricular hypertrophy in essential hypertension. Hypertens Res 2007; 30 (2) 125-131
• 4 Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension 1987; 9 (2 Pt 2, Suppl 2): II19-II26
• 5 Iwashima Y, Horio T, Kuroda S, Takishita S, Kawano Y. Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. Hypertens Res 2002; 25 (1) 49-56
• 6 Muscholl MW, Schunkert H, Muders F , et al. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. Am Heart J 1998; 135 (1) 58-66
• 7 Murro DG, Beavers M, Harshfield GA, Kapuku GK. Aldosterone contributes to elevated left ventricular mass in black boys. Pediatr Nephrol 2013; 28 (4) 655-660
• 8 Velagaleti RS, Gona P, Levy D , et al. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation 2008; 118 (22) 2252-2258
• 9 Schmidt BMW, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens 2003; 16 (1) 80-86
• 10 Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 1994; 23 (2) 258-268
• 11 Hülsmann M, Stanek B, Frey B , et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998; 32 (6) 1695-1700
• 12 Latini R, Masson S, Anand I , et al; Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25 (4) 292-299
• 13 Teerlink JR. Endothelins: pathophysiology and treatment implications in chronic heart failure. Curr Heart Fail Rep 2005; 2 (4) 191-197
• 14 Watanabe K, Sekiya M, Tsuruoka T, Funada J, Kameoka H. Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension. J Hypertens 1999; 17 (8) 1153-1160
• 15 Galvan AQ, Galetta F, Natali A , et al. Insulin resistance and hyperinsulinemia: No independent relation to left ventricular mass in humans. Circulation 2000; 102 (18) 2233-2238